Screener / SEC EDGAR /CIK 0001159036 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Halozyme Therapeutics, Inc. HALO

Compare with peers Embed
FY2025 at a glance

Sales up 37.6%, free cash flow up to $644.6M

XBRL, from each 10-K
RevenueStatements
$1.4B from $1.0B in FY2024
FY2016FY2025
Net incomeStatements
$316.9M from $444.1M in FY2024
FY2016FY2025
Free cash flowStatements
$644.6M from $468.4M in FY2024
FY2016FY2025
EPS (diluted)Statements
$2.56 from $3.43 in FY2024
FY2016FY2025
Operating marginStatements
33.6% from 54.3% in FY2024
FY2016FY2025
Total debtStatements
$2.1B from $1.5B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (42)
EPS (ttm)
4.00
Sales (ttm)
1.8B
Net income (ttm)
485.4M
Sales growth
+37.6%
EPS growth
-25.4%
Sales Q/Q
+39.2%
Free cash flow
885.9M
Gross margin
82.3%
Oper. margin
37.4%
Net margin
26.9%
FCF margin
49.1%
ROE
n/m
R&D / sales
5.8%
Dividend
-
Debt/Eq
n/m
Curr. ratio
3.88
Cash
1.0B
Op. cash flow (ttm)
898.3M
EBITDA
480.4M
EBITDA margin
34.4%
Net debt
2.2B
Quick ratio
3.51
Interest cover
25.87
FCF after stock pay
593.0M
Debt / FCF (years)
5.04
Goodwill / assets
23.0%
Oper. margin low 5y
33.6%
Tax rate
32.1%
Stock pay / sales
3.7%
Shares out.
114.0M
Shares Y/Y
-4.3%
Book / share
-0.48
Cash / share
9.03
Sales / share
15.81
Asset turnover
0.52
Inventory turns
1.30
Days sales out.
111
Sales 3Y CAGR
+28.4%
Sales 5Y CAGR
+39.2%
EPS 3Y CAGR
+21.1%
EPS 5Y CAGR
+23.0%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.4B +28.5% a year Net income 316.9M
FY2016 revenue 146.7M · Revenues, 0001159036-19-000006 FY2016 net income -103.0M · NetIncomeLoss, 0001159036-19-000006 146.7M FY2016 FY2017 revenue 316.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-20-000013 FY2017 net income 63.0M · NetIncomeLoss, 0001159036-20-000013 316.6M FY2017 FY2018 revenue 151.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-21-000014 FY2018 net income -80.3M · NetIncomeLoss, 0001159036-21-000014 151.9M FY2018 FY2019 revenue 196.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-22-000014 FY2019 net income -72.2M · NetIncomeLoss, 0001159036-22-000014 196.0M FY2019 FY2020 revenue 267.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-23-000012 FY2020 net income 129.1M · NetIncomeLoss, 0001159036-23-000012 267.6M FY2020 FY2021 revenue 443.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-24-000008 FY2021 net income 402.7M · NetIncomeLoss, 0001159036-24-000008 443.3M FY2021 FY2022 revenue 660.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-25-000010 FY2022 net income 202.1M · NetIncomeLoss, 0001159036-25-000010 660.1M FY2022 FY2023 revenue 829.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-26-000024 FY2023 net income 281.6M · NetIncomeLoss, 0001159036-26-000024 829.3M FY2023 FY2024 revenue 1.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-26-000024 FY2024 net income 444.1M · NetIncomeLoss, 0001159036-26-000024 1.0B FY2024 FY2025 revenue 1.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001159036-26-000024 FY2025 net income 316.9M · NetIncomeLoss, 0001159036-26-000024 1.4B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +24.3% a year FY2017 $0.45 to FY2025 $2.56, 8 years
Book value per share +1.5% a year FY2015 $0.34 to FY2025 $0.39, 10 years
Free cash flow per share +23.6% a year FY2017 $0.95 to FY2025 $5.20, 8 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $2.56$0.39$5.20
Dec 31, 2024 $3.43$2.81$3.62
Dec 31, 2023 $2.10$0.62$2.78
Dec 31, 2022 $1.44$1.21$1.67
Dec 31, 2021 $2.74$1.34$2.03
Dec 31, 2020 $0.91$1.07$0.37
Dec 31, 2019 -$0.50$0.64-$0.62
Dec 31, 2018 -$0.56$1.73-$0.38
Dec 31, 2017 $0.45$1.50$0.95
Dec 31, 2016 -$0.81-$0.25-$0.42
Dec 31, 2015 -$0.25$0.34-$0.31

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $825.2M
  • − All liabilities $2.5B
  • = Net current asset value -$1.7B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $48.8M
  • − Goodwill $580.4M
  • − Other intangible assets $981.5M
  • = Tangible book value -$1.5B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

HALO against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+37.6%21st of 155 · median +10.5%
Net margin
-4.1%15.3%
26.9%13th of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
49.1%2nd of 145 · median 10.0%
HALO and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
HALO Halozyme Therapeutics, Inc.$1.8B +37.6%82.3%26.9%-49.1%-
MSA MSA Safety Inc$2.0B +3.7%47.3%15.0%21.1%16.0%0.78
SRPT Sarepta Therapeutics, Inc.$2.0B +15.6%--5.9%-7.5%9.0%0.56
ITGR Integer Holdings Corp$1.8B +8.0%24.6%5.7%6.0%4.5%0.71
ALKS Alkermes plc.$1.8B -5.2%82.9%0.0%0.0%13.0%0.81
MMSI Merit Medical Systems Inc$1.6B +11.8%49.4%9.9%9.2%12.6%0.42
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement

From $660.1M of sales to $202.1M of profit FY2022

Revenue to Gross profit: $520.8MRevenue to Cost of revenue: $139.3MGross profit to Operating profit: $267.5MGross profit to Operating expenses: $253.3MOperating profit to Net profit: $202.1MOperating profit to Tax & other: $65.4MOperating expenses to R&D: $66.6MOperating expenses to Sales, admin & other: $186.7M Revenue: $660.1M REVENUE $660.1M +49% Y/Y Gross profit: $520.8M · 79% margin GROSS PROFIT $520.8M 79% margin Cost of revenue: $139.3M · 21% of revenue COST OF REVENUE $139.3M 21% of revenue Operating profit: $267.5M · 41% margin OPERATING PROFIT $267.5M 41% margin · −3% Y/Y Operating expenses: $253.3M · 38% of revenue OPERATING EXPENSES $253.3M 38% of revenue Net profit: $202.1M · 31% margin NET PROFIT $202.1M 31% margin · −50% Y/Y Tax & other: $65.4M · 10% of revenue TAX & OTHER $65.4M 10% of revenue R&D: $66.6M · 10% of revenue R&D $66.6M 10% of revenue Sales, admin & other: $186.7M · 28% of revenue SALES, ADMIN & OTHER $186.7M 28% of revenue

From $829.3M of sales to $281.6M of profit FY2023

Revenue to Gross profit: $636.9MRevenue to Cost of revenue: $192.4MGross profit to Operating profit: $337.6MGross profit to Operating expenses: $299.3MOperating profit to Net profit: $270.8MOperating profit to Tax: $66.7MOther income to Net profit: $10.8MOperating expenses to R&D: $76.4MOperating expenses to Sales, admin & other: $223.0M Revenue: $829.3M REVENUE $829.3M +26% Y/Y Gross profit: $636.9M · 77% margin GROSS PROFIT $636.9M 77% margin Cost of revenue: $192.4M · 23% of revenue COST OF REVENUE $192.4M 23% of revenue Operating profit: $337.6M · 41% margin OPERATING PROFIT $337.6M 41% margin · +26% Y/Y Other income: $10.8M · 1% of revenue OTHER INCOME $10.8M 1% of revenue Operating expenses: $299.3M · 36% of revenue OPERATING EXPENSES $299.3M 36% of revenue Net profit: $281.6M · 34% margin NET PROFIT $281.6M 34% margin · +39% Y/Y Tax: $66.7M · 8% of revenue TAX $66.7M 8% of revenue R&D: $76.4M · 9% of revenue R&D $76.4M 9% of revenue Sales, admin & other: $223.0M · 27% of revenue SALES, ADMIN & OTHER $223.0M 27% of revenue

From $1.0B of sales to $444.1M of profit FY2024

Revenue to Gross profit: $855.9MRevenue to Cost of revenue: $159.4MGross profit to Operating profit: $551.5MGross profit to Operating expenses: $304.4MOperating profit to Net profit: $444.1MOperating profit to Tax & other: $107.4MOperating expenses to R&D: $79.0MOperating expenses to Sales, admin & other: $225.4M Revenue: $1.0B REVENUE $1.0B +22% Y/Y Gross profit: $855.9M · 84% margin GROSS PROFIT $855.9M 84% margin Cost of revenue: $159.4M · 16% of revenue COST OF REVENUE $159.4M 16% of revenue Operating profit: $551.5M · 54% margin OPERATING PROFIT $551.5M 54% margin · +63% Y/Y Operating expenses: $304.4M · 30% of revenue OPERATING EXPENSES $304.4M 30% of revenue Net profit: $444.1M · 44% margin NET PROFIT $444.1M 44% margin · +58% Y/Y Tax & other: $107.4M · 11% of revenue TAX & OTHER $107.4M 11% of revenue R&D: $79.0M · 8% of revenue R&D $79.0M 8% of revenue Sales, admin & other: $225.4M · 22% of revenue SALES, ADMIN & OTHER $225.4M 22% of revenue

From $1.4B of sales to $316.9M of profit FY2025

Revenue to Gross profit: $1.2BRevenue to Cost of revenue: $228.8MGross profit to Operating profit: $469.0MGross profit to Operating expenses: $698.8MOperating profit to Net profit: $316.9MOperating profit to Tax & other: $152.1MOperating expenses to R&D: $81.5MOperating expenses to Sales, admin & other: $617.3M Revenue: $1.4B REVENUE $1.4B +38% Y/Y Gross profit: $1.2B · 84% margin GROSS PROFIT $1.2B 84% margin Cost of revenue: $228.8M · 16% of revenue COST OF REVENUE $228.8M 16% of revenue Operating profit: $469.0M · 34% margin OPERATING PROFIT $469.0M 34% margin · −15% Y/Y Operating expenses: $698.8M · 50% of revenue OPERATING EXPENSES $698.8M 50% of revenue Net profit: $316.9M · 23% margin NET PROFIT $316.9M 23% margin · −29% Y/Y Tax & other: $152.1M · 11% of revenue TAX & OTHER $152.1M 11% of revenue R&D: $81.5M · 6% of revenue R&D $81.5M 6% of revenue Sales, admin & other: $617.3M · 44% of revenue SALES, ADMIN & OTHER $617.3M 44% of revenue

Where each $100 of sales went

FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 649.2% FY2020: 85.5% net income ÷ equity
Net margin 22.7% FY2020: 48.2% profit per $ of sales: 316.9M ÷ 1.4B
Asset turnover 0.55× FY2020: 0.46× sales per $ of assets: 1.4B ÷ 2.5B
Leverage 51.73× FY2020: 3.84× assets per $ of equity: 2.5B ÷ 48.8M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    26.9% vs 6.8%
  • A profit in 7 of 10 years
Net margin, FY2016 to FY2025: -70.2% to 22.7%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 25.9× interest expense
  • Equity below zero
    Debt $3.3B, equity −$55.2M
  • Current assets cover current liabilities
    Current ratio 3.88
  • Net debt under 3 years of free cash flow
    $2.2B net debt, 2.5 years
Debt / equity at each year end, FY2016 to FY2025: 0.60 to 43.89

Cash and shareholders

  • Free cash flow positive in 7 of 10 years
    $644.6M last year
  • Share count down over 5 years
    −12.4%
  • Cash from operations above net income
    $651.6M vs $316.9M
Free cash flow, FY2016 to FY2025: -53.5M to 644.6M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$2.2B of principal due, schedule of Dec 31, 2025

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $30.3M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +261.9% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

HALO's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.4B
FY2016: 146.7MFY2017: 316.6MFY2018: 151.9MFY2019: 196.0MFY2020: 267.6MFY2021: 443.3MFY2022: 660.1MFY2023: 829.3MFY2024: 1.0BFY2025: 1.4B FY2017FY2019FY2021FY2023FY2025
Net income316.9M
FY2016: -103.0MFY2017: 63.0MFY2018: -80.3MFY2019: -72.2MFY2020: 129.1MFY2021: 402.7MFY2022: 202.1MFY2023: 281.6MFY2024: 444.1MFY2025: 316.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow644.6M
FY2016: -53.5MFY2017: 132.7MFY2018: -54.2MFY2019: -89.5MFY2020: 53.0MFY2021: 298.0MFY2022: 235.3MFY2023: 373.3MFY2024: 468.4MFY2025: 644.6M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay593.0M
FY2016: -79.1MFY2017: 102.0MFY2018: -89.9MFY2019: -124.2MFY2020: 35.7MFY2021: 277.2MFY2022: 210.9MFY2023: 336.7MFY2024: 425.0MFY2025: 593.0M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)2.56
FY2016: -0.81FY2017: 0.45FY2018: -0.56FY2019: -0.50FY2020: 0.91FY2021: 2.74FY2022: 1.44FY2023: 2.10FY2024: 3.43FY2025: 2.56 FY2017FY2019FY2021FY2023FY2025
Diluted shares123.9M
FY2016: 128.0MFY2017: 139.1MFY2018: 143.6MFY2019: 144.3MFY2020: 141.5MFY2021: 146.8MFY2022: 140.6MFY2023: 134.2MFY2024: 129.4MFY2025: 123.9M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Royalty payments 867.8M62.1% +52.0%
Proprietary product sales 194.6M13.9% +16.8%
Revenues under collaborative agreements 152.3M10.9% +8.2%
Bulk rHuPH20 sales 133.0M9.5% +54.1%
Sales-based milestones 70.0M5.0% +133%
Product sales to partners 48.8M3.5% -3.4%
Event-based development and regulatory milestones and other fees 47.0M3.4% -35.2%
Upfront license and target nomination fees 18.5M1.3% -31.6%
Device licensing and development revenue 16.9M1.2% +48.6%

10-K 0001159036-26-000024, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue146.7M316.6M151.9M196.0M267.6M443.3M660.1M829.3M1.0B1.4B
Cost of revenue33.2M31.2M10.1M45.5M43.4M81.4M139.3M192.4M159.4M228.8M
R&D150.8M150.6M150.3M140.8M34.2M35.7M66.6M76.4M79.0M81.5M
SG&A45.9M53.8M60.8M77.3M45.7M50.3M143.5M149.2M154.3M207.1M
Operating income-83.2M81.0M-69.3M-67.6M144.3M275.9M267.5M337.6M551.5M469.0M
Interest expense20.0M22.0M18.0M11.6M20.4M7.5M16.9M18.8M18.1M18.1M
Pretax income-101.9M61.6M-79.8M-72.3M129.3M248.5M248.9M348.3M557.1M466.9M
Income tax1.2M-1.4M537K-11K217K-154.2M46.8M66.7M113.0M150.0M
Net income-103.0M63.0M-80.3M-72.2M129.1M402.7M202.1M281.6M444.1M316.9M
EPS (diluted)-0.810.45-0.56-0.500.912.741.442.103.432.56
Diluted shares128.0M139.1M143.6M144.3M141.5M146.8M140.6M134.2M129.4M123.9M
Depreciation & amortization2.4M2.2M2.4M4.1M3.3M3.0M6.5M11.1M10.3M11.4M
EBITDA-80.8M83.2M-66.9M-63.5M147.5M278.9M274.0M348.7M561.7M480.4M
Operating margin-56.7%25.6%-45.7%-34.5%53.9%62.2%40.5%40.7%54.3%33.6%
Net margin-70.2%19.9%-52.9%-36.9%48.2%90.8%30.6%34.0%43.7%22.7%
Revenue growth+8.6%+116%-52.0%+29.1%+36.5%+65.7%+48.9%+25.6%+22.4%+37.6%
EPS growth--to a loss--+201%-47.4%+45.8%+63.3%-25.4%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-50.4M134.1M-49.5M-85.4M55.5M299.4M240.1M388.6M479.1M651.6M
Capital spending3.1M1.4M4.7M4.0M2.5M1.5M4.8M15.3M10.7M7.0M
Free cash flow-53.5M132.7M-54.2M-89.5M53.0M298.0M235.3M373.3M468.4M644.6M
Stock-based pay (added back)25.6M30.7M35.7M34.8M17.2M20.8M24.4M36.6M43.4M51.6M
Free cash flow after stock pay-79.1M102.0M-89.9M-124.2M35.7M277.2M210.9M336.7M425.0M593.0M
Buybacks-00200.0M150.1M350.1M200.0M402.4M250.0M342.4M
Acquisitions----00999.1M00726.0M
Debt raised203.0M00447.4M0784.9M00--
Investing cash flow-76.8M-163.7M2.5M-5.5M78.4M-406.3M-487.0M-96.9M-262.7M-545.8M
Financing cash flow150.6M131.7M-63.8M153.2M-106.3M77.9M362.4M-408.0M-218.9M-85.2M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)25.6M30.7M35.7M34.8M17.2M20.8M24.4M36.6M43.4M51.6M
Stock-based pay / revenue17.4%9.7%23.5%17.7%6.4%4.7%3.7%4.4%4.3%3.7%
Operating lease cost--2.4M2.6M2.2M1.9M3.3M8.0M7.9M8.7M
Operating lease cash paid--2.4M3.1M3.2M2.7M4.2M6.7M6.9M7.7M
Right-of-use assets--03.8M3.3M2.0M40.5M36.8M34.2M37.7M
Operating lease liabilities--06.5M4.9M2.8M34.8M32.2M30.7M34.6M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HALO/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.